Page last updated: 2024-11-07

dextroamphetamine and Infarction, Middle Cerebral Artery

dextroamphetamine has been researched along with Infarction, Middle Cerebral Artery in 1 studies

Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.

Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.

Research Excerpts

ExcerptRelevanceReference
"Administration of dextroamphetamine paired with 10 1-hour sessions of speech/language therapy facilitated recovery from aphasia in a small group of patients in the subacute period after stroke."5.09A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. ( Curtis, S; Dronkers, N; Ford, J; Lai, J; Natarajan, R; Salmeron, E; Unwin, DH; Walker-Batson, D, 2001)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Walker-Batson, D1
Curtis, S1
Natarajan, R1
Ford, J1
Dronkers, N1
Salmeron, E1
Lai, J1
Unwin, DH1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Single Blind, Controlled, Longitudinal Study of the Effects of Venlafaxine Hydrochloride Capsules on the Language Function of Stroke Patients With Subcortical Aphasia Using fMRI[NCT03588572]43 participants (Actual)Interventional2018-08-01Completed
Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463]Phase 288 participants (Anticipated)Interventional2021-07-18Recruiting
Trial of Propranolol in Older Adults With Primary Progressive Aphasia[NCT06066710]Early Phase 120 participants (Anticipated)Interventional2024-01-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

A Change of Outcome Measure:Picture Naming Test(PNT)

This test mainly assesses the ability of picture name of participants.we used a program for displaying named pictures on a computer screen (60 photos in total, of which 20 were Chinese celebrity faces). Each image was displayed in 3 seconds, and 1 point was correctly named for an image.The faces of celebrities were selected from the picture database of Chinese celebrities in the State Key Laboratory of Cognitive Neuroscience and Learning at Beijing Normal University.Score fluctuation is 0-60 points, the higher the score, the better the ability of picture name. (NCT03588572)
Timeframe: This is an outcome measure to assess the improvement of language function from onset to 3 months after treatment. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.

,
Interventionscore on a scale (Mean)
Visitation 1Visitation 2Visitation 3
Controlled Group38.3143.3148.31
Venlafaxine Group39.1946.7552.25

A Change of Outcome Measure:Spontaneous Language Frequency Test(SLFT)

This test mainly assesses spontaneous speech fluency of participants.It requires participants name as many food names as possible within one minute, and each correct one to give one point.The higher the score, the better the language function. (NCT03588572)
Timeframe: This is an outcome measure to assess the improvement of language function from onset to 3 months after treatment. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.

,
Interventionscore on a scale (Mean)
Visitation 1Visitation 2Visitation 3
Controlled Group5.758.1310.81
Venlafaxine Group5.319.3112.69

A Change of Outcome Measure:the Chinese Version of Western Aphasia Battery(WAB)

The main outcome measure for this scale is Aphasia Quotient(AQ) which mainly tests the ability of spontaneous speech, oral comprehension, repetition, and naming, and reflects the severity of aphasia, and can be used as a reliable indicator to evaluate the improvement and deterioration of aphasia. Score fluctuation is 0-100 points, the normal value is 98.4-100 points, AQ<93.8 can be judged as language dysfunction. (NCT03588572)
Timeframe: This is an outcome measure to assess the improvement of language function from onset to 3 months after treatment. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.

,
Interventionscore on a scale (Mean)
Visitation 1Visitation 2Visitation 3
Controlled Group78.6083.5188.55
Venlafaxine Group78.1688.2494.23

Follow-up Measurement: Hamilton Anxiety Rating Scale (HAMA)

The Hamilton Anxiety Rating Scale (HAMA) is a widely used and well-validated tool for measuring the severity of a patient's anxiety. The HAMA is composed of 14 items and takes 15-20 minutes to complete the interview and score the results. Each item is scored on a 5-point scale, ranging from 0=not present to 4=severe.HAMA Scoring Instructions:0-8=Normal, 8-13= Possible Anxiety, 14-17 = Mild Anxiety, 18-24 = Moderate Anxiety, 25-30 = Severe Anxiety(i.e.,the higher the score, the greater the likelihood of anxiety). (NCT03588572)
Timeframe: We must determine that the participant is not in anxiety at each follow-up. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.

,
Interventionscore on a scale (Mean)
Visitation 1Visitation 2Visitation 3
Controlled Group4.634.003.25
Venlafaxine Group4.884.133.56

Follow-up Measurement: Hamilton Depression Rating Scale (HAMD)

The Hamilton Depression Rating Scale (HAMD) has proven useful for many years as a way of determining a patient's level of depression before, during, and after treatment. It generally takes 15-20 minutes to complete the interview and score the results. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine items are scored from 0-2. HAMD Scoring Instructions:0-7=Normal, 8-13 = Mild Depression, 14-18 = Moderate Depression, 19-22 = Severe Depression, ≥ 23 = Very Severe Depression(i.e.,Minimum 0 points and maximum 50 points, the higher the score, the greater the likelihood of depression). (NCT03588572)
Timeframe: We must determine that the participant is not in depression at each follow-up. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.

,
Interventionscore on a scale (Mean)
Visitation 1Visitation 2Visitation 3
Controlled Group5.254.633.88
Venlafaxine Group5.634.944.06

Follow-up Measurement: Mini-Mental State Examination (MMSE)

The Mini-Mental State Examination (MMSE) is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. Administration of the test takes between 5 and 10 minutes. The MMSE test includes simple questions and problems in a number of areas: the time and place of the test, repeating lists of words, arithmetic such as the serial sevens, language use and comprehension, and basic motor skills. Any score greater than or equal to 24 points (out of 30) indicates a normal cognition. Below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment.The raw score may also need to be corrected for educational attainment and age. (NCT03588572)
Timeframe: We must determine that the participant is not in moderate or more cognitive impairment at each follow-up. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.

,
Interventionscore on a scale (Mean)
Visitation 1Visitation 2Visitation 3
Controlled Group23.8825.0026.19
Venlafaxine Group23.8125.3826.38

Trials

1 trial available for dextroamphetamine and Infarction, Middle Cerebral Artery

ArticleYear
A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia.
    Stroke, 2001, Volume: 32, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aphasia; Dextroamphetamine; Double-Blind Method; Female;

2001
A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia.
    Stroke, 2001, Volume: 32, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aphasia; Dextroamphetamine; Double-Blind Method; Female;

2001
A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia.
    Stroke, 2001, Volume: 32, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aphasia; Dextroamphetamine; Double-Blind Method; Female;

2001
A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia.
    Stroke, 2001, Volume: 32, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aphasia; Dextroamphetamine; Double-Blind Method; Female;

2001
A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia.
    Stroke, 2001, Volume: 32, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aphasia; Dextroamphetamine; Double-Blind Method; Female;

2001
A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia.
    Stroke, 2001, Volume: 32, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aphasia; Dextroamphetamine; Double-Blind Method; Female;

2001
A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia.
    Stroke, 2001, Volume: 32, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aphasia; Dextroamphetamine; Double-Blind Method; Female;

2001
A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia.
    Stroke, 2001, Volume: 32, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aphasia; Dextroamphetamine; Double-Blind Method; Female;

2001
A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia.
    Stroke, 2001, Volume: 32, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aphasia; Dextroamphetamine; Double-Blind Method; Female;

2001